The BPC-157 and TB-500 blend
BPC-157 and TB-500 are frequently studied together; a blend supplies both peptides in a single lyophilised vial for repair-related research.
BPC-157 and TB-500 are two of the most studied peptides in regenerative research, and they are frequently examined together. A blend supplies both in a single vial, which is why researchers working on repair-related models often ask about the combination.
Two complementary research peptides
BPC-157 is a synthetic pentadecapeptide derived from a protective protein found in gastric juice, studied for its role in tissue-repair and gastrointestinal-protection models. TB-500, a synthetic fragment of Thymosin beta-4, is studied for its role in actin regulation and cell migration. Our dedicated articles on BPC-157 and TB-500 cover each in detail.
Why they are studied together
In the published research literature the two are often paired because their mechanisms are seen as complementary: BPC-157 is examined mainly in growth-factor and vascular pathways, while TB-500 is examined mainly in the cytoskeletal dynamics that let cells migrate. Studying them together lets researchers probe how these distinct pathways interact in repair-related laboratory models.
What a blend is
A blend is simply the two peptides supplied together in one lyophilised vial, in a fixed ratio, rather than as two separate vials. It is reconstituted as a single solution, which some researchers prefer for consistency across a protocol.
Form and reconstitution
Like all research peptides, the blend ships as a lyophilised powder and is reconstituted with bacteriostatic water. Every Vela order includes a free 3 mL vial of bacteriostatic water, and our reconstitution guide covers the correct method.
Documented quality
Each batch is supplied with a certificate of analysis issued within six months of sale, documenting the identity and purity of both peptides for reproducible work.
Keep reading
More from the
research bench.
Retatrutide: the triple agonist explained
One molecule, three receptor pathways. Why retatrutide is one of the most closely watched compounds in modern metabolic research.
Tirzepatide: the dual GIP/GLP-1 agonist
How engaging two incretin pathways at once set tirzepatide apart, and what researchers study it for.
Why modified peptides last longer: half-life and modifications
How amino-acid substitutions, fatty-acid chains and added size extend a peptide's half-life, and why it matters in research.
